Net gain for the fourth one fourth of 2011 rose to $244,000, or $0.05 per share. This compares to net gain of $40,000, or $0.00 per share, for the fourth quarter of 2010.6 percent for the fourth quarter of 2011, and increased 7.1 percent for 2011, compared to the fourth one fourth and 2010, respectively. The full total number of methods performed in AMS’ Gamma Knife business increased 11.4 percent because of this year’s fourth one fourth, and increased 4.8 percent for 2011, when compared to fourth quarter and 2010, respectively. Gross margin for this year’s fourth one fourth decreased to 39.5 percent compared to 46.1 percent for the fourth quarter of 2010. This is primarily the result of a rise in depreciation expense linked to the upgrade of several Gamma Knife systems to Perfexion specs during the past 12 months.This theory is supported by animal studies. ‘The observation that high suPAR levels predict the future development of chronic kidney disease in various populations suggests this molecule may be a target for treatment to improve clinical outcomes in the majority of sufferers at risk for potential kidney disease. Blocking suPAR may end up being comparable in its program to the use of angiotensin switching enzyme inhibitors and angiotensin receptor blockers which are among the few medications approved for treatment of chronic kidney disease,’ said Howard Trachtman MD, a pediatric nephrologist at NYU Langone Medical Center and co-writer on the paper. Continuing to review suPAR Experts are continuing to study suPAR to identify types of the protein that are associated with various kinds of chronic kidney disease.